Перейти к содержимому

Acta Iuris Stetinensis

Acta Iuris Stetinensis

Ранее: Zeszyty Naukowe. Roczniki Prawnicze

4/2020 (32)
OpenAlex

Для всего журнала по данным OpenAlex.

Цитирования
239
Публикации
762
H-index
4
I10-index
2
Средняя цитируемость (2 года)
0,03
Полученные цитирования по годам
График цитирований журнала. Точные значения доступны в таблице ниже. 2017: 12 2018: 12 2019: 6 2020: 13 2021: 26 2022: 24 2023: 34 2024: 22 2025: 46 2026: 21 2017 2026
Показать таблицу данных
Полученные цитирования по годам
ГодПубликацииЦитирования
20175612
20184712
2019556
20203813
20217626
20228724
20236734
20248522
20255846
20264521

Данные загружены:

Что означают эти числа?

Публикации и цитирования охватывают записи, связанные с этим журналом в OpenAlex. H-индекс равен наибольшему числу h публикаций, каждая из которых цитируется не менее h раз. I10-индекс считает публикации с 10 и более цитированиями. График показывает цитирования, полученные в каждом году; текущий год неполный. Охват может отличаться от WNUS и других сервисов.

Средняя цитируемость за 2 года является показателем OpenAlex, а не Journal Impact Factor компании Clarivate.

Открыть в OpenAlex (новая вкладка)
Google Scholar

Misleading advertising practices for medicinal products and dietary supplements – selected legal and practical aspects

DOI: 10.18276/ais.2020.32-05
Цитировать

Полный текст доступен

Абстракт

The paper constitutes an attempt at analysing the issue of misleading advertising practices for medicinal products and dietary supplements. Furthermore, the aim of the paper was to provide an answer to the question whether the binding legal regulations concerning advertisement of medicinal products and dietary supplements sufficiently protect consumers against being misled. While studying the subject topic, in particular the dogmatic research method was used, through the agency of the analysis of legal provisions referring to the indicated issue and confrontation thereof with the practice applied in advertisements of medicinal products and dietary supplements. As a result of the conducted analysis of the indicated issue a conclusion has been drawn that the use of certain advertising practices on the pharmaceutical market may mislead consumers, which has a negative impact on public health. Having in mind the need for strengthening the consumers’ protection against the unfair advertisements of medicinal products and dietary supplements, the problems have been identified and it has been proposed to introduce legal regulations aimed at improvement of the consumers’ protection against practices that may be misleading.
Просмотр PDF

Открыть PDF

Библиография (13)
  1. Blum J, Trademarks in the pharmaceutical sector: the dynamic between brands, proprietary names and labelling regulations, in: Alemanno A. (ed.). The New Intellectual Property of Health Beyond Plain Packaging, Cheltenham 2016.
  2. Fry, J. N., Family branding and consumer brand choice, Journal of Marketing Research 1986, Vol. 4, No. 3, DOI:10.2307/3149455, access on: 01.02.2020.
  3. Ignatowicz, Z., Reklama produktów leczniczych (Advertisement of Medicinal Products), in: Olszewski W.L. (ed.) Prawo farmaceutyczne. Komentarz (The Pharmaceutical Law. Commentary), Warsaw 2016.
  4. Kondrat, M. et al. Prawo suplementów diety (The Dietary Supplements Law), Warsaw 2012,
  5. Ministry of Health, Polityka Lekowa Państwa 2018–2022 (State Drug Policy 2018–2022), 2018. https://www.gov.pl/web/zdrowie, access on: 01.02.2020.
  6. Makowska, M., Jasiński Ł., A discussion of the unresolved 2016/17 plans for regulating the Polish dietary supplements market, Health Policy 2019, Vol. 123, No. 6, DOI: 10.1016/j.healthpol.2019.04.001, access on: 1.02.2020.
  7. Mokrysz-Olszyńska, A., Advertising of dietary supplements as a challenge for legislator and regulator, Annals of the Administration and Law 2016, V. 16/2, 233-250.
  8. Mruk, H. et al., Marketing strategiczny na rynku farmaceutycznym (Strategic Marketing in the Pharmaceutical Market), Warsaw 2014.
  9. Pierewoj, J., Suplement diety a bezpieczeństwo konsumentów – wybrane aspekty prawa polskiego oraz prawa Unii Europejskiej (Dietary Supplement vs Consumers’ Safety – Selected Aspects of the Polish Law and the European Union Law), in: Porzeżyński, M., Borcuch A. (eds.), Bezpieczeństwo w erze społeczeństwa informacyjnego. Wyzwania w sferach kultury, marketingu i gospodarki (Safety in the Era of Information Society. Challenges for Culture, Marketing and Economy), Kielce 2019.
  10. Roszak, M., Granice stosowania praktyki umbrella brandingu (znaków parasolowych) na rynku farmaceutycznym (Restrictions in Applying the Umbrella Branding in the Pharmaceutical Market), in: Kępiński M. (ed.), Rynek farmaceutyczny, a prawo własności intelektualnej (The Pharmaceutical Market vs the Intellectual Property Right), Warsaw 2013.
  11. Supreme Audit Office, Dopuszczenie do obrotu suplementów diety (Admission of Dietary Supplements to Trading), 2017. https://www.nik.gov.pl/, access on: 01.02.2020.
  12. Szczęsny, R., Reklama farmaceutyczna i pokrewna (Pharmaceutical and Related Advertisement), Warsaw 2010.
  13. The Ministry of Health, The Report of the Team for Regulating Advertisement of Medicines, Dietary Supplements and Other Foodstuff and Medicinal Products, 2016, https://www.gov.pl/web/zdrowie/, access on: 20.02.2020.